Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
ALPMY's Cash to Debt is ranked higher than
100% of the 773 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.62 vs. ALPMY: No Debt )
ALPMY' s 10-Year Cash to Debt Range
Min: 19.46   Max: No Debt
Current: No Debt

Equity to Asset 0.77
ALPMY's Equity to Asset is ranked higher than
82% of the 714 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.61 vs. ALPMY: 0.77 )
ALPMY' s 10-Year Equity to Asset Range
Min: 0.73   Max: 0.78
Current: 0.77

0.73
0.78
F-Score: 7
Z-Score: 6.90
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Revenue Growth (%) -0.60
ALPMY's Revenue Growth (%) is ranked higher than
59% of the 629 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.10 vs. ALPMY: -0.60 )
ALPMY' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 1.4
Current: -0.6

0
1.4
EBITDA Growth (%) -3.00
ALPMY's EBITDA Growth (%) is ranked higher than
63% of the 594 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.60 vs. ALPMY: -3.00 )
ALPMY' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: -3
Current: -3

EPS Growth (%) 3.40
ALPMY's EPS Growth (%) is ranked higher than
71% of the 595 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.00 vs. ALPMY: 3.40 )
ALPMY' s 10-Year EPS Growth (%) Range
Min: 0   Max: 54.3
Current: 3.4

0
54.3
» ALPMY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with ALPMY



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 9.70
ALPMY's P/E(ttm) is ranked higher than
98% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 41.40 vs. ALPMY: 9.70 )
ALPMY' s 10-Year P/E(ttm) Range
Min: 3.92   Max: 433.99
Current: 9.7

3.92
433.99
P/B 2.40
ALPMY's P/B is ranked higher than
76% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.22 vs. ALPMY: 2.40 )
ALPMY' s 10-Year P/B Range
Min: 0.26   Max: 2.5
Current: 2.4

0.26
2.5
P/S 13.95
ALPMY's P/S is ranked higher than
92% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.55 vs. ALPMY: 13.95 )
ALPMY' s 10-Year P/S Range
Min: 0.34   Max: 14
Current: 13.95

0.34
14
PFCF 11.20
ALPMY's PFCF is ranked higher than
97% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. ALPMY: 11.20 )
ALPMY' s 10-Year PFCF Range
Min: 1.26   Max: 65.11
Current: 11.2

1.26
65.11
EV-to-EBIT 22.82
ALPMY's EV-to-EBIT is ranked higher than
81% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 32.81 vs. ALPMY: 22.82 )
ALPMY' s 10-Year EV-to-EBIT Range
Min: 0.9   Max: 111.9
Current: 22.82

0.9
111.9
Shiller P/E 25.00
ALPMY's Shiller P/E is ranked higher than
88% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. ALPMY: 25.00 )
ALPMY' s 10-Year Shiller P/E Range
Min: 19.33   Max: 26.53
Current: 25

19.33
26.53
Current Ratio 2.68
ALPMY's Current Ratio is ranked higher than
74% of the 761 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.31 vs. ALPMY: 2.68 )
ALPMY' s 10-Year Current Ratio Range
Min: 2.38   Max: 3.64
Current: 2.68

2.38
3.64
Quick Ratio 2.28
ALPMY's Quick Ratio is ranked higher than
76% of the 761 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.68 vs. ALPMY: 2.28 )
ALPMY' s 10-Year Quick Ratio Range
Min: 1.99   Max: 3.22
Current: 2.28

1.99
3.22

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.90
ALPMY's Dividend Yield is ranked higher than
68% of the 453 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.37 vs. ALPMY: 1.90 )
ALPMY' s 10-Year Dividend Yield Range
Min: 1.81   Max: 4.11
Current: 1.9

1.81
4.11
Dividend growth (3y) -19.60
ALPMY's Dividend growth (3y) is ranked higher than
65% of the 317 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.50 vs. ALPMY: -19.60 )
ALPMY' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 23.3
Current: -19.6

0
23.3
Yield on cost (5-Year) 0.95
ALPMY's Yield on cost (5-Year) is ranked lower than
62% of the 461 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.39 vs. ALPMY: 0.95 )
ALPMY' s 10-Year Yield on cost (5-Year) Range
Min: 0.91   Max: 2.06
Current: 0.95

0.91
2.06
Share Buyback Rate -6.70
ALPMY's Share Buyback Rate is ranked higher than
63% of the 556 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -1.70 vs. ALPMY: -6.70 )
ALPMY' s 10-Year Share Buyback Rate Range
Min: 0   Max: -53.9
Current: -6.7

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 116.00
ALPMY's Price/Net Current Asset Value is ranked higher than
79% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. ALPMY: 116.00 )
ALPMY' s 10-Year Price/Net Current Asset Value Range
Min: 1.14   Max: 300.28
Current: 116

1.14
300.28
Price/Tangible Book 14.70
ALPMY's Price/Tangible Book is ranked higher than
74% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. ALPMY: 14.70 )
ALPMY' s 10-Year Price/Tangible Book Range
Min: 0.29   Max: 3.14
Current: 14.7

0.29
3.14
Price/DCF (Projected) 23.60
ALPMY's Price/DCF (Projected) is ranked higher than
79% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. ALPMY: 23.60 )
ALPMY' s 10-Year Price/DCF (Projected) Range
Min: 0.25   Max: 5.3
Current: 23.6

0.25
5.3
Price/Median PS Value 4.20
ALPMY's Price/Median PS Value is ranked higher than
77% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.20 vs. ALPMY: 4.20 )
ALPMY' s 10-Year Price/Median PS Value Range
Min: 0.46   Max: 2.85
Current: 4.2

0.46
2.85
Price/Graham Number 9.50
ALPMY's Price/Graham Number is ranked higher than
80% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.60 vs. ALPMY: 9.50 )
ALPMY' s 10-Year Price/Graham Number Range
Min: 0.17   Max: 2.06
Current: 9.5

0.17
2.06
Earnings Yield (Greenblatt) 4.40
ALPMY's Earnings Yield (Greenblatt) is ranked higher than
71% of the 624 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.90 vs. ALPMY: 4.40 )
ALPMY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.9   Max: 111.9
Current: 4.4

0.9
111.9
Forward Rate of Return (Yacktman) -15.47
ALPMY's Forward Rate of Return (Yacktman) is ranked higher than
54% of the 622 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.97 vs. ALPMY: -15.47 )
ALPMY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -19   Max: 9.5
Current: -15.47

-19
9.5

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare: » details
Traded in other countries:4503.Japan, YPH.Germany
Astellas Pharma Inc is engaged in the business of manufacturing, marketing and import/export of pharmaceuticals. The Company's businesses are segmented into pharmaceutical and other.
» More Articles for OTCPK:ALPMY

Headlines

Articles On GuruFocus.com
“Patience is a necessary virtue for value investors” – A Look into the International Value Inv Jun 06 2014 
Charles De Vaulx Reports His Top Five of the First Quarter Jun 03 2014 
IVA International's Charles De Vaulx Reports His Year End Top Stocks Mar 05 2014 
Top Guru-Held Stocks of Asia, Where David Winters Sees Biggest Potential in 2014 Dec 18 2013 
Charles De Vaulx's Top Third Quarter Stocks Nov 27 2013 
Jean-Marie Eveillard's First Eagle Global Fund Third Quarter Commentary Dec 05 2012 

More From Other Websites
Astellas Up on Pipeline Update, Oncology in Focus (revised) Jul 21 2014
Astellas' Isavuconazole Gets QIDP for Invasive Candidiasis Jul 17 2014
Astellas Up on Pipeline Update, Oncology in Focus Jul 16 2014
Astellas Seeks FDA Nod for Fungal Infection Treatment Jul 10 2014
Making Money Around The World Jun 13 2014
Patients Enrolled in Avanir Study Jun 02 2014
Pipeline Update from Avanir Jun 02 2014
New England Journal of Medicine Publishes Results from Phase 3 PREVAIL Trial of Enzalutamide in Men... Jun 01 2014
CHMP Negative on Novartis' RLX030 May 27 2014
Data on Novo Nordisk's NovoEight May 16 2014
Setback for Novartis' RLX030 May 16 2014
Enzalutamide Data, Including Additional Results From the PREVAIL Trial, To be Presented at Upcoming... May 14 2014
QLT Inc. (QLTI) Falls: Stock Goes Down 9.13% May 14 2014
Shire to Acquire Lumena May 13 2014
Pipeline Progress at Roche May 12 2014
Valeant Beats on Earnings in Q1 May 12 2014
Corcept Therapeutics (CORT) in Focus: Stock Rises 5.8% May 12 2014
NPS Pharmaceuticals (NPSP) Jumps: Stock Up 13.9% May 12 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide